Small, Medium API-Makers In Indian Economy Squeeze Seen Merging
This article was originally published in PharmAsia News
Small and medium-size makers of active pharmaceutical ingredients in India are suffering from an increase in costs they are unable to pass on to buyers. Many of the companies also are being hurt by dampened enthusiasm for their shares, adding to the squeeze. As a result, industry analysts see a flurry of consolidation in the API-making industry in India by the middle of next year. But at least one analyst sees that as an opportunity for healthy companies to buy the smaller firms. (Click here for more
You may also be interested in...
Deputy CEO Nicolas Hieronimus will take L’Oreal’s helm beginning in May 2021, with Jean-Paul Agon continuing as chairman, the firm announced on 14 October. The Estee Lauder Companies hires PepsiCo’s Gibu Thomas to lead its online business, and Coty appoints its first chief digital officer.
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.